03202019Headline:

Incidence and Prevalence of Cancer will creates an opportunities for in Vaccine Adjuvants Market

Download FREE Brochure: http://bit.ly/2N6hmwG

According to new market research report published by MarketsandMarkets, the vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5%. This market is segmented based on product type, route of administration, disease type, applications, and application category.

On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.

Based on disease type, the vaccine adjuvants market comprises of infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global market in 2016. High prevalence of infectious diseases and cancer is expected to drive market growth in the coming years.

Based on applications, the vaccine adjuvants market is segmented into research applications and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to factors such as ongoing research on new adjuvants, increasing initiatives by government bodies and companies.

Vaccine Adjuvants Market

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Get More Detailed information: http://bit.ly/2O8Itnc

What Next?

Related Articles